Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CVM $0.65 0.0540 +9.11%
GALT $2.71 0.1500 +5.86%
DRNA $13.93 0.6400 +4.82%
ALDR $46.94 1.3000 +2.85%
TLOG $2.35 0.0300 +1.29%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BPTH $1.09 -0.1950 -15.23%
ARQL $1.53 -0.1800 -10.53%
ONTY $3.52 -0.3850 -9.87%
EPZM $20.47 -1.9800 -8.82%
HTBX $6.00 -0.5300 -8.12%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

Novartis Data at EHA Show Increased PFS Benefit of Farydak® in New Subgroup of Patients with Previously Treated Multiple Myeloma

(MarketWatch) June 12, 2015 - Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival (PFS) when using Farydak® (panobinostat, previously known as LBH589) in combination with bortezomib* and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.
read article 



A New Targeted Combination Therapy with Potential to Eliminate Relapsed Chronic Lymphocytic Leukemia

(EHA) June 12, 2015 – Promising results from an early phase trial combining the anti-bcl-2 drug Venetoclax with Rituximab to eliminate CLL are presented by Dr Andrew Roberts.
read press release 



FDA Clears Novartis' Promacta for Paediatric ITP Patients

(PharmaTimes [UK]) June 12, 2015 - The US Food and Drug Administration has expanded the scope of Novartis’ immune thrombocytopenia drug Promacta to treat children with the rare clotting disorder.
read article 



Agios 'Cancer Metabolism' Drugs Induce Prolonged Responses in Blood Cancer Patients

(TheStreet) June 12, 2015 - Two experimental drugs from Agios Pharmaceuticals designed to curb the overactive metabolism of certain kinds of mutated blood cancer cells are showing prolonged responses not normally seen in patients with advanced disease, according to new study results announced Friday.
read article 



Arzerra Improved Median Progression-Free Survival by 54% in Patients with Relapsed Chronic Lymphocytic Leukaemia

(European Pharmaceutical Review) June 12, 2015 - Novartis has presented promising data from the Phase III COMPLEMENT 2 study of Arzerra® (ofatumumab) in patients with replapsed chronic lymphocytic leukaemia (CLL) at the 20th Congress of the European Hematology Association (EHA).
read article 



Agios Leukemia Drug Demonstrates Impressive Response Rate: Study

(Reuters) June 12, 2015 - Forty percent of patients, most with a particularly aggressive form of leukemia, responded to an experimental Agios Pharmaceuticals Inc drug, including several who experienced complete remission, according to data presented at a medical meeting on Friday.
read article 



Novartis Gains FDA Approval for Promacta® Providing New Option for Children, Ages 6 and Older, With Chronic ITP, a Rare Blood Disorder

(StreetInsider) June 11, 2015 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Promacta® (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
read article 



Op-Ed: Don’t Weaken the F.D.A.’s Drug Approval Process

(New York Times) June 11, 2015 - The 21st Century Cures Act could substantially lower the standards for approval of many medical products, potentially placing patients at unnecessary risk of injury or death.
read article 



AstraZeneca Chief Medical Officer Departing to Join Small Biotech Firm

(The Guardian [UK]) June 10, 2015 - Briggs Morrison, who joined drug maker in 2012 and defended it against a takeover by Pfizer, leaving for un-named company in ‘matter of weeks’.
read article 



U.S. Shifts Stance on Drug Pricing in Pacific Trade Pact Talks, Document Reveals

(New York Times) June 10, 2015 - Facing resistance from Pacific trading partners, the Obama administration is no longer demanding protection for pharmaceutical prices under the 12-nation Trans-Pacific Partnership, according to a newly leaked section of the proposed trade accord.
read article 



FDA Advisory Panel Backs Amgen's Cholesterol-Lowering Drug Repatha

(Morningstar/Dow Jones) June 10, 2015 - A Food and Drug Administration advisory committee on Wednesday recommended that the agency approve Amgen Inc.'s cholesterol-lowering drug Repatha, the second in a class of promising heart medicines that could change medical practice and generate billions of dollars in sales.
read article 



Alternative Payment Models Offer Hope for Future of Cancer Care

(The Hill/Congress blog) June 11, 2015 - Radiation oncologists can make individually tailored treatment decisions that are decoupled from inefficient fee-for-service payment models and narrow and inadequate care pathways.
read article 



NCCN Receives $2 Million in Research Funding from Boehringer Ingelheim to Study Targeted Combination Approaches with Afatinib in Lung Cancer

(NCCN) June 11, 2015 - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to evaluate scientifically targeted combination approaches with afatinib in the treatment of non-small cell lung cancer (NSCLC).
read press release 



Personal Genome Diagnostics Launches LungSelect™ For Non-Invasive Detection of Clinically Actionable Mutations in Lung Cancer

(Yahoo! Finance) June 11, 2015 - Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its LungSelect™ product that identifies the most common, clinically actionable genetic alterations in the plasma of non-small cell lung cancer (NSCLC) patients.
read article 



BioNTech Launches MammaTyper® Breast Cancer Diagnostic

(BioNTech) June 11, 2015 - BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies and its subsidiary BioNTech Diagnostics GmbH, today announced the launch of MammaTyper®, a CE-IVD marked molecular diagnostic test to stratify breast cancer patients by molecular subtyping of routine tumor tissue, for universal use in pathology laboratories.
read corporate press release 



NeoGenomics Launches Twelve NeoLAB™ "Liquid Biopsy" Tests for Hematologic Diseases

(CNN Money) June 11, 2015 - NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of its first twelve tests in a new line of "liquid biopsy" or NeoLAB™ assays using next generation sequencing and other advanced molecular technologies.
read article 



Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

(MarketWatch) June 10, 2015 - Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-120 for treatment of patients with acute myelogenous leukemia (AML).
read article 



Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma

(CNN Money) June 10, 2015 - Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that the FDA has granted orphan status to the company's lead product candidate, LN-144, for the treatment of stage 2b to stage 4 malignant melanoma.
read article 



Cancer Drug 'Not Cost-Effective'

(Yahoo! News UK/Press Association) June 10, 2015 - Cancer charities have reacted with disappointment to news that a drug to treat advanced prostate cancer has not been deemed cost-effective for the NHS by health officials.
read article 



Penn Study Shows Nearly 10 Percent of Women Live Too Far From Access to Gynecologic Cancer Care

(Penn Medicine) June 11, 2015 - Findings reveal gaps in specialty care for ovarian, uterine and cervical cancer throughout United States.
read press release 



Celyad Completes 30-Day Safety Follow-Up of First Patient in NKG2D Phase I Trial

(Morningstar) June 10, 2015 - Celyad SA, today announced the completion of the 30-day safety follow-up of the first patient enrolled in the Company’s Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM).
read article 



Bristol-Myers Squibb Demonstrates Commitment to Hematology and Advancing Research and Development Across Multiple Blood Cancers Through Immuno-Oncology Leadership at the 20th Congress of the European Hematology Association

(BMS) June 11, 2015 - Bristol-Myers Squibb will present data for elotuzumab, an investigational immunostimulatory antibody, in relapsed or refractory multiple myeloma; Opdivo (nivolumab), in patients with relapsed or refractory lymphoid malignancies; and Sprycel (dasatinib), in chronic myeloid leukemia.
read corporate press release 



Petri Dish Tumor Test Could Personalize Drug Therapy for Cancer Patients

(UW-Madison) June 11, 2015 - In a highly successful, first-of-its-kind endeavor, a multidisciplinary team of University of Wisconsin-Madison researchers has created a "tumor in a dish:" an ex vivo microenvironment that can accurately anticipate a multiple myeloma patient's response to a drug.
read article 



MD Anderson Study Finds Gene Mutations Sensitize Tumors to Specific Cancer Drugs

(MD Anderson) June 11, 2105 - Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles’ heel when treating certain tumors, according to MD Anderson researchers.
read press release 



ADAMTS Family of Genes May Be the Next ‘Thing’ in Ovarian Cancer Treatment

(MD Anderson) June 11, 2015 - MD Anderson study reveals key mutations other than well-known BRCA1/BRCA2 genes.
read press release